{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:26:32Z","timestamp":1778621192181,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"crossref","award":["R381-A23024"],"award-info":[{"award-number":["R381-A23024"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"crossref","award":["R378-A22530"],"award-info":[{"award-number":["R378-A22530"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021851","name":"William Demant Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021851","name":"William Demant Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021851","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Danish Lymphoma Group"},{"DOI":"10.13039\/501100024879","name":"Janssen Cilag","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024879","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bneo.2025.100128","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T12:23:42Z","timestamp":1749471822000},"page":"100128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4499-3126","authenticated-orcid":false,"given":"Trine","family":"Trab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7670-1880","authenticated-orcid":false,"given":"Iman","family":"Chanchiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8739-0421","authenticated-orcid":false,"given":"Ahmed Ludvigsen","family":"Al-Mashhadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma Berggren","family":"Dall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stine","family":"Rasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-1173","authenticated-orcid":false,"given":"Simon","family":"Husby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1119-4782","authenticated-orcid":false,"given":"Mikkel Runason","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3218-3633","authenticated-orcid":false,"given":"Michael Roost","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-6708","authenticated-orcid":false,"given":"Thomas Stauffer","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1071-3218","authenticated-orcid":false,"given":"Jacob Haaber","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Schou","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-6707","authenticated-orcid":false,"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-1378","authenticated-orcid":false,"given":"Christian Bj\u00f8rn","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8715-2749","authenticated-orcid":false,"given":"Laura Mors","family":"Haunstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6522-4086","authenticated-orcid":false,"given":"Peter","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-380X","authenticated-orcid":false,"given":"Tarec Christoffer","family":"El-Galaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-9601","authenticated-orcid":false,"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bneo.2025.100128_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.bneo.2025.100128_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.16317","article-title":"Comorbidities and sex differences in causes of death among mantle cell lymphoma patients \u2013 a nationwide population-based cohort study","volume":"189","author":"Glimelius","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100128_bib3","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/bloodadvances.2022007241","article-title":"Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation","volume":"7","author":"Ekberg","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.bneo.2025.100128_bib4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100128_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000510","article-title":"Detailed long-term follow-up of patients who relapsed after the Nordic Mantle Cell Lymphoma trials: MCL2 and MCL3","volume":"5","author":"Eskelund","year":"2021","journal-title":"Hemasphere"},{"issue":"suppl 4","key":"10.1016\/j.bneo.2025.100128_bib6","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100128_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HS9.0000000000000928","article-title":"Nationwide assessment of patient trajectories in mantle cell lymphoma: the Swedish MCL complete project","volume":"7","author":"Jerkeman","year":"2023","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.bneo.2025.100128_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bneo.2025.100128_bib9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"10020","key":"10.1016\/j.bneo.2025.100128_bib10","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.bneo.2025.100128_bib11","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"10441","key":"10.1016\/j.bneo.2025.100128_bib12","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100128_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2024-200735","article-title":"Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: results from the Randomized Triangle trial By the European MCL Network","volume":"144","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2025.100128_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157999","article-title":"The Danish national lymphoma registry: coverage and data quality","volume":"11","author":"Arboe","year":"2016","journal-title":"PLoS One"},{"issue":"27","key":"10.1016\/j.bneo.2025.100128_bib15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bneo.2025.100128_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"1","key":"10.1016\/j.bneo.2025.100128_bib17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ije\/dyu222","article-title":"Modelling recurrent events: a tutorial for analysis in epidemiology","volume":"44","author":"Amorim","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.bneo.2025.100128_bib18","series-title":"A Language and Environment for Statistical Computing","year":"2022"},{"issue":"21","key":"10.1016\/j.bneo.2025.100128_bib19","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1182\/blood.V124.21.4471.4471","article-title":"Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2025.100128_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000712","article-title":"Long-term outcomes with ibrutinib treatment for patients with relapsed\/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up","volume":"6","author":"Dreyling","year":"2022","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.bneo.2025.100128_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bneo.2025.100128_bib22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100128_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100128_bib24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","article-title":"Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"182","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100128_bib25","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100128_bib26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/bjh.17363","article-title":"Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients","volume":"193","author":"McCulloch","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100128_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-022-05023-2","article-title":"Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic","volume":"102","author":"Obr","year":"2023","journal-title":"Ann Hematol"},{"issue":"16","key":"10.1016\/j.bneo.2025.100128_bib28","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/bloodadvances.2023009804","article-title":"Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed\/refractory mantle cell lymphoma","volume":"7","author":"Villa","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.bneo.2025.100128_bib29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12185-022-03367-z","article-title":"IBRORS-MCL study: a Spanish retrospective and observational study of relapsed\/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice","volume":"116","author":"Sancho","year":"2022","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100128_bib30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bjh.16922","article-title":"Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study","volume":"192","author":"Sharman","year":"2021","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.bneo.2025.100128_bib31","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-sex-and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.bneo.2025.100128_bib32","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1080\/10428194.2024.2390561","article-title":"The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide study","volume":"65","author":"Simonsen","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.bneo.2025.100128_bib33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/10428194.2022.2157676","article-title":"Australian experience with ibrutinib in patients with relapsed\/refractory mantle cell lymphoma: a study from the lymphoma and related diseases registry","volume":"64","author":"Baggio","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.bneo.2025.100128_bib34","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/bjh.16739","article-title":"The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed\/refractory mantle cell lymphoma","volume":"192","author":"Tucker","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100128_bib35","first-page":"373","article-title":"Ibrutinib in patients with relapsed\/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the \u201cRTL\u201d (regional Tuscan Lymphoma Network)","volume":"11","author":"Cencini","year":"2021","journal-title":"Am J Blood Res"},{"issue":"4","key":"10.1016\/j.bneo.2025.100128_bib36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma\u2014a \u201creal world\u201d study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100128_bib37","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bneo.2025.100128_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8262787","article-title":"Outcomes among patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States: a real-world electronic medical records study","volume":"2022","author":"Hess","year":"2022","journal-title":"Adv Hematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100128_bib39","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjh.18519","article-title":"Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study","volume":"202","author":"Hess","year":"2023","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100128_bib40","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16416","article-title":"Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","volume":"189","author":"McCulloch","year":"2020","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100128_bib41","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2025.100128_bib42","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1016\/S2152-2650(22)01569-5","article-title":"MCL-133 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1\/2 BRUIN study","volume":"22","author":"Cohen","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"10.1016\/j.bneo.2025.100128_bib43","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bneo.2025.100128_bib44","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.bneo.2025.100128_bib45","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100128_bib46","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1080\/10428194.2017.1375110","article-title":"Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors","volume":"59","author":"Tang","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.bneo.2025.100128_bib47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.bneo.2025.100128_bib48","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"10121","key":"10.1016\/j.bneo.2025.100128_bib49","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1016\/j.bneo.2025.100128_bib50","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100128_bib51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma\u2014consensus guidelines of the pathology panel of the European MCL Network","volume":"2","author":"Klapper","year":"2009","journal-title":"J Hematop"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:12:02Z","timestamp":1756127522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2950328025000639"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100128","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100128"}}